Drug intelligence / Profile preview

adamgammadex (Aomo Pharma Inc.)

Development stage: Unknown
Lead developer: Hangzhou Adamerck Pharmlabs
Modality: Small Molecules
Administration: Intravenous

Overview

Adamgammadex (Aom0499) is a novel small molecule neuromuscular blockade reversal agent developed by Aomo Pharma. It is designed to effectively reverse cisatracurium-induced neuromuscular blockade, acting through a new target and mechanism distinct from existing agents. Adamgammadex aims to compete with sugammadex (Bridion) and other neuromuscular reversal agents, targeting the global market for nondepolarizing muscle relaxant antagonists. As of the latest available information, it has undergone Phase I clinical trials evaluating its safety, tolerability, and pharmacokinetics in healthy subjects[5].

Other names: adamgammadex sodium

Targets

Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on adamgammadex (Aomo Pharma Inc.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adamgammadex (Aomo Pharma Inc.).

Explore the full profile